Evolent Health Inc. (NYSE:EVH) – Stock analysts at William Blair dropped their Q4 2016 earnings per share estimates for shares of Evolent Health in a research report issued on Tuesday. William Blair analyst R. Daniels now forecasts that the brokerage will post earnings per share of ($0.15) for the quarter, down from their prior forecast of ($0.14). William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Evolent Health’s FY2017 earnings at ($0.32) EPS.
Evolent Health (NYSE:EVH) last posted its earnings results on Thursday, August 4th. The company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.16) by $0.04. Evolent Health had a negative return on equity of 5.04% and a negative net margin of 76.55%. The company had revenue of $56.50 million for the quarter, compared to analyst estimates of $51.96 million. During the same period last year, the company earned ($0.95) earnings per share. The business’s revenue was up 443.3% compared to the same quarter last year.
Other equities analysts also recently issued research reports about the stock. Jefferies Group started coverage on shares of Evolent Health in a report on Tuesday, July 26th. They set a “buy” rating and a $28.00 price target on the stock. FBR & Co lifted their price target on shares of Evolent Health from $24.00 to $26.00 and gave the company an “outperform” rating in a report on Friday, August 5th. Leerink Swann reaffirmed an “outperform” rating and set a $20.00 price target on shares of Evolent Health in a report on Sunday, July 17th. Canaccord Genuity set a $30.00 price target on shares of Evolent Health and gave the company a “buy” rating in a report on Wednesday, September 28th. Finally, Zacks Investment Research downgraded shares of Evolent Health from a “hold” rating to a “sell” rating in a report on Wednesday. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Evolent Health currently has a consensus rating of “Buy” and a consensus target price of $22.50.
Evolent Health (NYSE:EVH) opened at 24.84 on Thursday. The company’s market capitalization is $1.50 billion. Evolent Health has a 1-year low of $8.14 and a 1-year high of $26.84. The stock has a 50 day moving average price of $23.77 and a 200-day moving average price of $18.27.
In other news, major shareholder Board Co Advisory sold 1,936,529 shares of the business’s stock in a transaction on Wednesday, September 14th. The shares were sold at an average price of $22.50, for a total value of $43,571,902.50. Following the transaction, the insider now owns 4,445,879 shares of the company’s stock, valued at $100,032,277.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Frank J. Williams sold 251,481 shares of the business’s stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $21.54, for a total transaction of $5,416,900.74. Following the completion of the transaction, the chief executive officer now directly owns 1,304,799 shares in the company, valued at approximately $28,105,370.46. The disclosure for this sale can be found here. 8.85% of the stock is currently owned by insiders.
Several institutional investors have recently added to or reduced their stakes in the company. Pennant Capital Management LLC increased its position in Evolent Health by 54.2% in the first quarter. Pennant Capital Management LLC now owns 1,361,147 shares of the company’s stock valued at $14,374,000 after buying an additional 478,318 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of Evolent Health by 39.0% in the first quarter. JPMorgan Chase & Co. now owns 1,290,465 shares of the company’s stock valued at $13,628,000 after buying an additional 361,945 shares in the last quarter. Perceptive Advisors LLC boosted its stake in shares of Evolent Health by 41.1% in the second quarter. Perceptive Advisors LLC now owns 873,064 shares of the company’s stock valued at $16,763,000 after buying an additional 254,134 shares in the last quarter. Blair William & Co. IL boosted its stake in shares of Evolent Health by 205.5% in the second quarter. Blair William & Co. IL now owns 341,570 shares of the company’s stock valued at $6,558,000 after buying an additional 229,748 shares in the last quarter. Finally, TimesSquare Capital Management LLC boosted its stake in shares of Evolent Health by 21.1% in the first quarter. TimesSquare Capital Management LLC now owns 1,192,755 shares of the company’s stock valued at $12,595,000 after buying an additional 207,755 shares in the last quarter. 40.22% of the stock is currently owned by hedge funds and other institutional investors.
Evolent Health Company Profile
Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.
Receive News & Ratings for Evolent Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.